<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="Central and other publicly funded repositories, such as the WHO" exact="COVID" post="database with rights for unrestricted research re-use and analyses"/>
 <result pre="resource centre remains active. Early December 2019, and an epidemic" exact="pneumonia" post="caused by a novel coronavirus infection (later named as"/>
 <result pre="December 2019, and an epidemic pneumonia caused by a novel" exact="coronavirus infection" post="(later named as COVID-19 by WHO) was recorded in"/>
 <result pre="2019, and an epidemic pneumonia caused by a novel coronavirus" exact="infection" post="(later named as COVID-19 by WHO) was recorded in"/>
 <result pre="recorded in the city of Wuhan, Hubei province, China; the" exact="viral infection" post="was soon to spread widely across China. As of"/>
 <result pre="in the city of Wuhan, Hubei province, China; the viral" exact="infection" post="was soon to spread widely across China. As of"/>
 <result pre="this compares with mortality rates of 10% for Middle East" exact="Respiratory" post="Syndrome (MERS-CoV) and 37% for Severe Acute Respiratory Syndrome"/>
 <result pre="compares with mortality rates of 10% for Middle East Respiratory" exact="Syndrome" post="(MERS-CoV) and 37% for Severe Acute Respiratory Syndrome (SARS-CoV)."/>
 <result pre="10% for Middle East Respiratory Syndrome (MERS-CoV) and 37% for" exact="Severe" post="Acute Respiratory Syndrome (SARS-CoV). More urgently, this novel coronavirus"/>
 <result pre="for Middle East Respiratory Syndrome (MERS-CoV) and 37% for Severe" exact="Acute" post="Respiratory Syndrome (SARS-CoV). More urgently, this novel coronavirus is"/>
 <result pre="Middle East Respiratory Syndrome (MERS-CoV) and 37% for Severe Acute" exact="Respiratory" post="Syndrome (SARS-CoV). More urgently, this novel coronavirus is spreading"/>
 <result pre="East Respiratory Syndrome (MERS-CoV) and 37% for Severe Acute Respiratory" exact="Syndrome" post="(SARS-CoV). More urgently, this novel coronavirus is spreading across"/>
 <result pre="protease (PLpro), RNA-dependent RNA polymerase (RdRp) and helicase. During the" exact="viral infection" post="process, including intracellular transport of virions, proliferation and assembling"/>
 <result pre="(PLpro), RNA-dependent RNA polymerase (RdRp) and helicase. During the viral" exact="infection" post="process, including intracellular transport of virions, proliferation and assembling"/>
 <result pre="targeting these proteins or enzymes as a therapy against SARS-CoV-2" exact="infection" post="could be a promising strategy. To date, no special"/>
 <result pre="permitted to be used in an attempt to combat the" exact="disease" post="in clinical trials. Remdesivir and favipiravir interfere with the"/>
 <result pre="clinical trials. Remdesivir and favipiravir interfere with the synthesis of" exact="viral" post="mRNA targeting RdRp. Remdesivir is being developed by Gilead"/>
 <result pre="for Ebola but it also shows potential against coronavirus and" exact="Nipah virus infection." post="The results from evaluating the antiviral efficiency of remdesivir"/>
 <result pre="Ebola but it also shows potential against coronavirus and Nipah" exact="virus infection." post="The results from evaluating the antiviral efficiency of remdesivir"/>
 <result pre="1.76 μM [3]. Remdesivir cured the first case of SARS-CoV-2" exact="infection" post="confirmed in the USA, which prompted Gilead and the"/>
 <result pre="reverse transcriptase inhibitors that were approved to treat HIV and" exact="hepatitis" post="B virus (HBV). Currently, only one trial combines emtricitabine/tenofovir-alafenamide"/>
 <result pre="patients. Arbidol as a 2′-5′oligoadenylates synthesis (OAS) inhibitor against severe" exact="pneumonia" post="and virus-associated cytokine dysregulation has displayed anti-SARS-CoV-2 potential in"/>
 <result pre="authorities have approved chloroquine phosphate to be used to treat" exact="adult" post="patients suffering from SARS-CoV-2 infection. Further, treatments combining Traditional"/>
 <result pre="harm’ should still be the top priority. References References 1WHOCoronavirus" exact="disease" post="(COVID-2019) situation reportsAvailable at:2020https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ 2LuR.Genomic characterisation and epidemiology of"/>
</results>
